Metall Zug AG (METN) AI Stock Analysis

• Market Cap: $412.41M
• Dividend Yield: 2.08%
• Average Volume (3M): 281.00
• Price to Earnings (P/E): 8.6
• Beta (1Y): 0.53
• Revenue Growth: -56.09%
• EPS Growth: -118.83%
• Country: CH
• Employees: 983
• Sector: Industrials
• Sector Strength: 74
• Industry: Conglomerates
• EPS (TTM): -21.78
• Shares Outstanding: 255,136
• 10 Day Avg. Volume: 303
• 30 Day Avg. Volume: 281
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 2.29
• Enterprise Value/Gross Profit: 7.13
• Enterprise Value/Ebitda: 9.79
• 1Y Price Target: $1,085.26
• Price Target Upside: 18.74% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: CHF1,082.00 ▲(18.38% Upside)

The overall stock score is primarily influenced by the company's strong valuation, with a low P/E ratio and reasonable dividend yield. However, financial performance challenges, particularly in cash flow, and weak technical indicators weigh down the score. The absence of recent earnings call data and notable corporate events limits additional insights.

Metall Zug AG Business Overview & Revenue Model

Company Description

Metall Zug AG (METN) is a Swiss-based industrial holding company that operates primarily in the sectors of medical technology, precision engineering, and production of machinery and equipment. The company is known for its diverse portfolio, which includes the manufacture of high-quality medical devices, advanced technologies for the production of precision components, and specialized machinery for various industries. Metall Zug AG is committed to innovation and sustainability, aiming to provide efficient and cutting-edge solutions to its global clientele.

How the Company Makes Money

Metall Zug AG generates revenue through multiple key streams, primarily from its operations in medical technology and precision engineering. The company earns money by manufacturing and selling medical devices, which are used in hospitals and healthcare facilities worldwide. Additionally, it produces precision components for various industries, contributing to its revenue through direct sales and long-term contracts with clients. The company has established significant partnerships with healthcare organizations and industrial players, enhancing its market reach and stability. Furthermore, Metall Zug AG benefits from ongoing investments in research and development, enabling it to introduce innovative products that cater to evolving market demands, thus driving sales growth and profitability.

Metall Zug AG Financial Statement Overview

Summary

Metall Zug AG faces challenges in maintaining revenue growth and profitability while demonstrating strong balance sheet stability with low leverage. However, negative cash flow trends pose risks to financial flexibility, necessitating improvements in cash-generating activities to support future operations.

Income Statement

The company has shown volatile revenue trends with a significant decline in recent years. Gross profit margin has been relatively stable but with a decreasing trend in total revenue. The net profit margin improved from previous losses, indicating better cost management, but overall profitability remains a challenge.

Balance Sheet

The company maintains a strong equity ratio and low debt levels, which enhances financial stability. However, the decrease in stockholders' equity and total assets over the years poses concerns about long-term asset management and growth potential.

Cash Flow

Free cash flow has been negative in recent years, indicating insufficient cash generation to support capital expenditures and other financial obligations. The operating cash flow has also declined, highlighting potential liquidity issues.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	283.42M	494.71M	645.94M	661.89M	823.54M
Gross Profit	90.95M	151.65M	226.69M	228.21M	261.41M
EBITDA	68.07M	43.12M	146.21M	57.62M	40.97M
Net Income	52.59M	22.22M	129.98M	48.78M	14.31M
Balance Sheet
Total Assets	632.95M	690.66M	701.19M	715.63M	635.24M
Cash, Cash Equivalents and Short-Term Investments	17.25M	29.80M	31.73M	81.84M	72.27M
Total Debt	82.81M	36.60M	17.00M	4.17M	4.65M
Total Liabilities	146.54M	168.84M	182.89M	199.44M	152.34M
Stockholders Equity	419.24M	455.51M	453.36M	450.94M	418.25M
Cash Flow
Free Cash Flow	-31.13M	-26.71M	-40.72M	14.27M	14.20M
Operating Cash Flow	2.77M	9.52M	-5.93M	48.98M	60.26M
Investing Cash Flow	-53.54M	-16.41M	-41.81M	-32.35M	-63.23M
Financing Cash Flow	37.44M	6.89M	-17.63M	-8.21M	-76.13M

Metall Zug AG Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 914.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:METN, the sentiment is Negative. The current price of 914 is below the 20-day moving average (MA) of 969.15, below the 50-day MA of 1001.44, and below the 200-day MA of 1042.35, indicating a bearish trend. The MACD of -17.93 indicates Positive momentum. The RSI at 30.77 is Neutral, neither overbought nor oversold. The STOCH value of 11.83 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CH:METN.

Metall Zug AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	$10.73B	15.74	7.56%	2.01%	2.76%	-15.10%
METN	58 Neutral	$412.41M	8.56	-3.04%	2.08%	-56.09%	-118.83%
FEIOF	―	$197.81M	22.35	-9.74%	2.89%	―	―
0QQF	―	CHF303.26M	9.68	14.20%	2.70%	―	―
SCWTF	―	$568.65M	80.47	0.83%	2.58%	―	―
ELMN	74 Outperform	CHF274.19M	32.49		0.17%	-0.64%	-5.79%
ARBN	55 Neutral	CHF400.22M	3.27		74.78%	―	―

Metall Zug AG Corporate Events

Metall Zug AG Shareholders Approve Board Proposals and Sustainability Initiatives

At the 138th ordinary general meeting, Metall Zug AG’s shareholders approved all board proposals, including the election of Sandrine Zweifel to the board, a cash dividend distribution, and a contribution to the Greenhouse Gas Fund. These decisions align with the company’s strategic focus on sustainability and ophthalmology, potentially enhancing its industry positioning and stakeholder relations.